- Datum24.02.2025
- Uhrzeit08:00 - 09:00 Uhr
- Veranstalter
XTB
Kala Pharmaceuticals Chart

Charts analysieren
wie die Profis?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse und handle direkt aus dem Chart bei Deinem Broker.
Chart analysieren
Kala Pharmaceuticals Realtime-Kurs
Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
---|---|---|---|---|---|---|
L&S | VK | |||||
Tradegate | VK | |||||
Stuttgart | VK |
Passende Produkte
WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
---|
Wertentwicklung (Nasdaq)
Wikifolio
Passender Service zu Kala Pharmaceuticals
Webinar zu Kala Pharmaceuticals
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)4,210-11,200
- Jahrestief / Hoch ($)6,500-11,200
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Kala Pharmaceuticals
Termine von Kala Pharmaceuticals
Beschreibung
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing innovative therapies for rare and severe eye diseases. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.